- Home
- ADUR vs CLLS Comparison
ADUR vs CLLS Comparison
Compare ADUR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUR
- CLLS
- Stock Information
- Founded
- ADUR 2011
- CLLS 1999
- Country
- ADUR Canada
- CLLS France
- Employees
- ADUR N/A
- CLLS N/A
- Industry
- ADUR
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ADUR
- CLLS Health Care
- Exchange
- ADUR NYSE
- CLLS Nasdaq
- Market Cap
- ADUR 162.6M
- CLLS 143.4M
- IPO Year
- ADUR N/A
- CLLS 2007
- Fundamental
- Price
- ADUR $11.75
- CLLS $1.83
- Analyst Decision
- ADUR Strong Buy
- CLLS Buy
- Analyst Count
- ADUR 1
- CLLS 1
- Target Price
- ADUR $48.00
- CLLS $4.00
- AVG Volume (30 Days)
- ADUR 307.6K
- CLLS 128.3K
- Earning Date
- ADUR 01-01-0001
- CLLS 08-05-2025
- Dividend Yield
- ADUR N/A
- CLLS N/A
- EPS Growth
- ADUR N/A
- CLLS N/A
- EPS
- ADUR N/A
- CLLS N/A
- Revenue
- ADUR $179,327.00
- CLLS $54,747,000.00
- Revenue This Year
- ADUR N/A
- CLLS $48.52
- Revenue Next Year
- ADUR N/A
- CLLS $5.17
- P/E Ratio
- ADUR N/A
- CLLS N/A
- Revenue Growth
- ADUR N/A
- CLLS 351.26
- 52 Week Low
- ADUR $3.25
- CLLS $1.10
- 52 Week High
- ADUR $12.40
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- ADUR N/A
- CLLS 60.54
- Support Level
- ADUR N/A
- CLLS $1.85
- Resistance Level
- ADUR N/A
- CLLS $2.36
- Average True Range (ATR)
- ADUR 0.00
- CLLS 0.16
- MACD
- ADUR 0.00
- CLLS 0.04
- Stochastic Oscillator
- ADUR 0.00
- CLLS 48.06
About ADUR ADURO CLEAN TECHNOLOGIES INC
Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.